Leerink Partners Upgrades Johnson & Johnson to Outperform, Raises Price Target
Wednesday / 05/20/2026, 17:16 EST
Leerink Partners upgraded Johnson & Johnson to Outperform from Market Perform, raising its price target to $265. The firm cites strong drug momentum and expects accelerated revenue growth.
